Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Integrin α1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy.
Yu L, Su Y, Paueksakon P, Cheng H, Chen X, Wang H, Harris RC, Zent R, Pozzi A.
Kidney Int. 2012 Jun;81(11):1086-97. doi: 10.1038/ki.2011.474. Epub 2012 Feb 1.
Related citations
Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion.
Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, Yoshimoto S, Samejima K, Yamaguchi Y, Matsui M, Akai Y, Konishi N, Iwano M, Nabeshima Y, Saito Y.
Kidney Int. 2012 Mar;81(6):539-47. doi: 10.1038/ki.2011.423. Epub 2012 Jan 4.
The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
Hirst JA, Taylor KS, Stevens RJ, Blacklock CL, Roberts NW, Pugh CW, Farmer AJ.
Kidney Int. 2012 Apr;81(7):674-83. doi: 10.1038/ki.2011.413. Epub 2011 Dec 21.
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group.
Kidney Int. 2012 Mar;81(6):586-94. doi: 10.1038/ki.2011.415. Epub 2011 Dec 14.
Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes.
Moriya T, Tsuchiya A, Okizaki S, Hayashi A, Tanaka K, Shichiri M.
Kidney Int. 2012 Mar;81(5):486-93. doi: 10.1038/ki.2011.404. Epub 2011 Dec 7.
Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.
Batlle D, Wysocki J, Soler MJ, Ranganath K.
Kidney Int. 2012 Mar;81(6):520-8. doi: 10.1038/ki.2011.381. Epub 2011 Nov 23.
Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury.
Covington MD, Schnellmann RG.
Kidney Int. 2012 Feb;81(4):391-400. doi: 10.1038/ki.2011.356. Epub 2011 Oct 19.
Is there a deleterious effect of erythropoietin in end-stage renal disease?
Singh AK.
Kidney Int. 2011 Sep;80(6):569-71. doi: 10.1038/ki.2011.190.
Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.
Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, Mayr M, Tam FW.
Kidney Int. 2011 Oct;80(8):851-60. doi: 10.1038/ki.2011.224. Epub 2011 Aug 10.
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.
Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA.
Kidney Int. 2011 Sep;80(6):663-9. doi: 10.1038/ki.2011.188. Epub 2011 Jun 22.
Error occurred: cannot get document summary
Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy.
Fugmann T, Borgia B, Révész C, Godó M, Forsblom C, Hamar P, Holthöfer H, Neri D, Roesli C.
Kidney Int. 2011 Aug;80(3):272-81. doi: 10.1038/ki.2011.116. Epub 2011 May 4.
Tubular biomarkers to assess progression of diabetic nephropathy.
Tramonti G, Kanwar YS.
Kidney Int. 2011 May;79(10):1042-4.
An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Grüner S, Green L, Mattei P, Hartmann G, Anders HJ.
Kidney Int. 2011 Jul;80(1):68-78. doi: 10.1038/ki.2011.102. Epub 2011 Apr 20.
Proteinuria in a patient with diabetes.
Kunaparaju S, Okafor C, Cathro H, Bhola V, Ballenger FJ, Rosner MH.
Kidney Int. 2011 Apr;79(7):793-4. No abstract available.
Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease.
Chang GY, Park AS, Susztak K.
Kidney Int. 2011 Apr;79(8):802-4.
An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes.
Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC, Rich SS, Warram JH, Krolewski AS.
Kidney Int. 2011 Jul;80(1):105-11. doi: 10.1038/ki.2011.64. Epub 2011 Mar 16.
Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor.
Gilbert RE, Huang Q, Thai K, Advani SL, Lee K, Yuen DA, Connelly KA, Advani A.
Kidney Int. 2011 Jun;79(12):1312-21. Epub 2011 Mar 9.
Support for a protective effect of bilirubin on diabetic nephropathy in humans.
Zelle DM, Deetman N, Alkhalaf A, Navis G, Bakker SJ.
Kidney Int. 2011 Mar;79(6):686; author reply 686-7. No abstract available.
Need for better diabetes treatment for improved renal outcome.
Rossing P, de Zeeuw D.
Kidney Int Suppl. 2011 Mar;(120):S28-32. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on